{"id":"NCT02932943","sponsor":"Naurex, Inc, an affiliate of Allergan plc","briefTitle":"A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-15","primaryCompletion":"2018-09-21","completion":"2018-11-08","firstPosted":"2016-10-13","resultsPosted":"2019-10-11","lastUpdate":"2019-10-11"},"enrollment":465,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Rapastinel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rapastinel 450 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial","timeFrame":"Baseline and 3 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":-5,"sd":0.54},{"arm":"Rapastinel 450 mg","deltaMin":-4.7,"sd":0.54}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6482"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":226},"commonTop":["Headache","Dysgeusia"]}}